COMMUNIQUÉS West-GlobeNewswire

Wellthy Acquires Patch Caregiving to Expand Innovative Childcare with On-Site and Near-Site Backup Care Solutions
06/10/2025
Acquisition strengthens Wellthy’s leadership in family care, bringing new options for employers with in-person and hybrid workforces New York, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Wellthy , the leading platform helping [...]
Foundation for Sarcoidosis Research Celebrates 25 Years of Innovation, Empowerment, and Progress at Anniversary Awards Gala
06/10/2025
CHICAGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR), the leading international nonprofit organization dedicated to improving the lives of those impacted by sarcoidosis, will host its [...]
SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors
06/10/2025
TEL AVIV, Israel, Oct. 06, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat [...]
OneMedNet Selects Palantir to Advance Healthcare AI and Data Analytics
06/10/2025
DENVER and MINNEAPOLIS, Oct. 06, 2025 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) has selected Palantir Technologies (Nasdaq: PLTR) to transform the healthcare AI and Real-World Data (RWD) analytics [...]
Verano Provides Update on the Canadian Postal Strike, the Company’s Special Meeting Materials and Voting Instructions
06/10/2025
CHICAGO, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, is advising shareholders that due to the ongoing [...]
Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial
06/10/2025
Nimacimab monotherapy did not meet its primary endpoint for weight loss; preliminary pharmacokinetic analysis showed lower than expected drug exposure, potentially indicating the need for higher dosing as a monotherapy [...]
ImprimisRx Announces Leadership Changes
06/10/2025
Frank Mullery Appointed Chief Executive Officer of ImprimisRx Bridseida Cruz Appointed Head of Quality of ImprimisRx NASHVILLE, Tenn., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of [...]
Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives
06/10/2025
NEWTOWN, Pa., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical [...]
Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM)
06/10/2025
Following Scientific Advice and Guidance from Scientific Advice Working Party (SAWP) of EMA, Submission of CMA Application for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) WM Expected in Early 2026 [...]
USA Pickleball Grants Official Approval and Certification for J-Star’s First In-House Pickleball Paddle, Horizon
06/10/2025
TAICHUNG CITY, Taiwan, Oct. 06, 2025 (GLOBE NEWSWIRE) -- J-Star Holding Co., Ltd. (Nasdaq: YMAT) (“J-Star” or the “Company”), a leading provider of innovative carbon fiber and composite solutions across a wide range of [...]
Exicure Highlights Recent Achievements and Near-term Strategic Priorities
06/10/2025
Burixafor (GPC-100) Phase 2 Trial in Multiple Myeloma Nears Key Readout Preparing for Expansion into Sickle Cell Disease and Acute Myeloid Leukemia New Leadership Appointments Bring Deep Drug Development Expertise [...]
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study
06/10/2025
Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission Positive ENLIGHTEN 2 results highlighted at the AAO-HNS 2025 Annual Meeting WATERTOWN, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE [...]
Chiesi Group and Arbor Biotechnologies Announce a Global Strategic Partnership to Develop Novel Rare Disease Gene Editing Programmes
06/10/2025
Exclusive collaboration and license agreement for the development and global commercialisation of Arbor’s clinical-stage gene editing programme, ABO-101 for primary hyperoxaluria type 1 (PH1) Multitarget research [...]
Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025
06/10/2025
Company to present three posters at SITC Annual Meeting 2025 BOSTON, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and [...]
Chiesi Group and Arbor Biotechnologies Announce a Global Strategic Partnership to Develop Novel Rare Disease Gene Editing Programs
06/10/2025
Exclusive collaboration and license agreement for the development and global commercialization of Arbor’s clinical-stage gene editing program, ABO-101 for primary hyperoxaluria type 1 (PH1) Multitarget research [...]
Soleo Health Named Pioneer in URAC’s Leaders in Performance Measurement
06/10/2025
FRISCO, Texas, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Soleo Health , an innovative leader and national provider of complex specialty pharmacy services, announced today it is a Specialty Pharmacy Pioneer recipient of URAC’s [...]
Eccogene Receives U.S. FDA Clearance to Initiate Phase 2a MOSAIC Trial of ECC4703 and ECC0509 for MASH
06/10/2025
BOSTON and SHANGHAI, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory [...]
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
06/10/2025
Mr. Hoppenot, a seasoned biotech leader who has driven transformative therapies to market, joins Maze to fuel its evolution into a leading clinical-stage biotech SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE [...]
Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
06/10/2025
The DECLARATION (safety and efficacy vs. placebo) and LIBERTY (exploratory safety head-to-head and combination with mRNA-based COVID vaccination) clinical trials are expected to begin around year-end 2025; top-line data [...]

Pages